CEL-SCI's patented inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.
The LEAPS platform technology, currently being developed as a therapeutic vaccine for rheumatoid arthritis under a USD 1.5m grant from the US National Institutes of Health, is a T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens.
LEAPS compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This platform technology has been shown in several animal models to preferentially direct the immune response to a cellular, humoral, or mixed pathway and has been shown to involve upregulation of T-regulatory cells in some animal models.
It has the potential to be utilised in diseases for which antigenic epitope sequences have already been identified, such as: a number of infectious diseases, some cancers, autoimmune diseases, allergic asthma and allergy, and select central nervous system diseases.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
Sanofi acquires DR-0201 from Dren Bio to expand immunology pipeline
InnoCare reports first patient dosed in Phase II/III vitiligo trial
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
CARsgen reports positive preliminary clinical data for CT0596 in R/R MM
RTW Biotech portfolio company Jade Biosciences merges with Aerovate Therapeutics